Rezafungin Prophylaxis in Liver Transplant
Enrolling by invitation · Phase 3 · NCT06774144
Conditions: Liver Transplant Infection, Fungal Infection
At a glance
- Research payments reported, 2025
- $100,000
- U.S. investigators named
- 2
- Sites paid
- 1
- Planned or actual enrollment
- 385
About the trial
- Sponsor
- Fernanda P Silveira, MD, MS (with Melinta Therapeutics)
- Tested
- Rezafungin (drug), Standard of care antifungal prophylaxis (drug)
- Dates
- Started 2025-10-15; completion 2028-12
- Results posted
- Not yet
This is an interventional study to evaluate the efficacy of rezafungin, a new echinocandin, for the prevention of invasive fungal infections (IFIs) after liver transplantation. Patients who receive rezafungin will be compared to a similar group of patients who underwent liver transplantation in the preceding two years for the incidence of IFIs.
From ClinicalTrials.gov, last updated 2026-09-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Melinta Therapeutics, LLC reported $100,000 in research payments for this study in 2025 (1 payments).
Products named: Rezzayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Minh-hong Nguyen Infectious Disease · Pittsburgh, PA
- Fernanda Silveira, MD Infectious Disease · Pittsburgh, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Pittsburgh $100,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.